Cytek Biosciences (CTKB) Gains from Sales and Divestitures (2022 - 2023)
Cytek Biosciences (CTKB) reported Gains from Sales and Divestitures of $260297.0 for Q2 2023, up 238.09% on a YoY basis from $76990.0 in Q2 2022, and up 218.84% quarter-over-quarter from $81639.0 in Q1 2023.
Cytek Biosciences (CTKB) Gains from Sales and Divestitures (2022 - 2023) Analysis & Trends
Cytek Biosciences has reported Gains from Sales and Divestitures for 2 years, with the latest figure at $260297.0 in Q2 2023.
- For the quarter ending Q2 2023, Gains from Sales and Divestitures rose 238.09% year-over-year to $260297.0; the trailing twelve-month figure through Jun 2023 stood at $260297.0 (up 238.09% YoY), and the FY2022 full-year result was $215433.0, changed N/A from the prior year.
- Gains from Sales and Divestitures for Q2 2023 stood at $260297.0, up from $81639.0 in the prior quarter.
- The five-year high for Gains from Sales and Divestitures was $260297.0 in Q2 2023, with the low at $76990.0 in Q2 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 154.42 Bn | 147.76 Bn | 6.27 Bn |
| 2 | Stryker | 118.12 Bn | 115.25 Bn | 3.81 Bn |
| 3 | Medtronic | 101.72 Bn | 93.55 Bn | 5.76 Bn |
| 4 | Boston Scientific | 67.19 Bn | 65.98 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 50.69 Bn | 47.02 Bn | 1.29 Bn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn |
| 7 | Dexcom | 28.09 Bn | 26.97 Bn | 750.30 Mn |
| 8 | GE HealthCare Technologies | 28.08 Bn | 26.02 Bn | 1.98 Bn |
| 9 | Steris | 19.80 Bn | 19.37 Bn | 697.10 Mn |
| 10 | Cytek Biosciences | - | - | 21.25 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 260,297.00 |
| Jun 30, 2023 | 260,297.00 |
| Mar 31, 2023 | 81,639.00 |
| Mar 31, 2023 | 81,639.00 |
| Dec 31, 2022 | 215,433.00 |
| Dec 31, 2022 | 215,433.00 |
| Sep 30, 2022 | 135,476.00 |
| Sep 30, 2022 | 135,476.00 |
| Jun 30, 2022 | 76,990.00 |
| Jun 30, 2022 | 76,990.00 |